Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oratopo dose-finding study in advanced solid tumors
NCT03987685Phase 1Completed
- Sponsor
- Athenex
- Start
- Jul 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of topotecan + HM30181A in solid tumor, sponsored by Athenex. Primary endpoint: Maximum Tolerated Dose. Started Jul 2018; status: completed.
02
Drugs
topotecan + HM30181A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03987685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987685.